American Journal of Ophthalmology
Volume 148, Issue 5 , Pages 696-703.e1 , November 2009

High-dose Daclizumab for the Treatment of Juvenile Idiopathic Arthritis–Associated Active Anterior Uveitis

  • H. Nida Sen

      Affiliations

    • National Eye Institute, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationInquiries to H. Nida Sen, National Eye Institute, National Institutes of Health, 10 Center Dr, Bldg 10 Rm:10N112, Bethesda, MD 20892
    • ,
  • Grace Levy-Clarke

      Affiliations

    • National Eye Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Lisa J. Faia

      Affiliations

    • National Eye Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Zhuqing Li

      Affiliations

    • National Eye Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Steven Yeh

      Affiliations

    • National Eye Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Karyl S. Barron

      Affiliations

    • National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • John G. Ryan

      Affiliations

    • National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Keri Hammel

      Affiliations

    • EMMES Corp, Rockville, Maryland
    • ,
  • Robert B. Nussenblatt

      Affiliations

    • National Eye Institute, National Institutes of Health, Bethesda, Maryland

,Accepted 1 June 2009.

References 

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392
  2. Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with anti-nuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005;52:826–832
  3. Kotaniemi K, Kautiainen H, Karma A, Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001;108:2071–2075
  4. Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2003;14:395–398
  5. Chalom EC, Goldsmith DP, Koehler MA, et al. Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. J Rheumatol. 1997;24:2031–2034
  6. Zulian F, Martini G, Falcini F, et al. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol. 2002;29:2446–2453
  7. Chia A, Lee V, Graham EM, Edelsten C. Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol. 2003;135:757–762
  8. Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647–655
  9. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104:236–244
  10. Wolf MD, Lichter PR, Ragsdale CG. Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology. 1987;94:1242–1248
  11. Edelsten C, Lee V, Bentley CR, et al. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002;86:51–56
  12. Rosenberg AM, Oen KG. The relationship between ocular and articular disease activity in children with juvenile rheumatoid arthritis and associated uveitis. Arthritis Rheum. 1986;29:797–800
  13. Chen CS, Roberton D, Hammerton ME. Juvenile arthritis-associated uveitis: visual outcomes and prognosis. Can J Ophthalmol. 2004;39:614–620
  14. Key SN, Kimura SJ. Iridocyclitis associated with juvenile rheumatoid arthritis. Am J Ophthalmol. 1975;80:425–429
  15. Özdal PC, Vianna RN, Deschênes J. Visual outcomes of juvenile rheumatoid arthritis-associated uveitis in adults. Ocul Immunol Inflamm. 2005;13:33–38
  16. Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143:840–846
  17. Chylack LT. The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20:S217–S223
  18. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362–365
  19. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory noninfectious childhood uveitis. Br J Ophthalmol. 1998;82:737–742
  20. Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548–550
  21. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor a inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45:982–989
  22. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308–314
  23. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23
  24. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation (Daclizumab Triple Therapy Study Group). N Engl J Med. 1998;338:161–165
  25. Bumgardner GL, Hardie I, Johnson RW, et al. Phase III Daclizumab Study Group Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 2001;72:839–845
  26. Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun. 2008;31:91–97
  27. Gallagher M, Quinones K, Cervantes-Castañeda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91:1341–1344
  28. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology. 2005;112:764–770
  29. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 1999;96:7462–7466
  30. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21:283–293
  31. Jabs DA, Nussenblatt RB, Rosenbaum JT Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data (Results of the First International Workshop). Am J Ophthalmol. 2005;140:509–516
  32. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45:982–989
  33. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860–864
  34. Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112:1066–1071
  35. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110:786–789
  36. Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: In vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol. 2005;174:5187–5191

PII: S0002-9394(09)00403-6

doi: 10.1016/j.ajo.2009.06.003

American Journal of Ophthalmology
Volume 148, Issue 5 , Pages 696-703.e1 , November 2009

Article Tools

* Image Usage & Resolution